- Home
- CGC vs LXEO Comparison
CGC vs LXEO Comparison
Compare CGC & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGC | LXEO |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.3M | 369.8M |
| IPO Year | 2023 | 2023 |
Fundamental Metrics
Financial Performance| Metric | CGC | LXEO |
|---|---|---|
| Price | $1.03 | $4.53 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | N/A | ★ $18.44 |
| AVG Volume (30 Days) | ★ 6.8M | 724.3K |
| Earning Date | 05-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 36.75 | ★ 39.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,759,000.00 | $654,000.00 |
| Revenue This Year | $8.27 | N/A |
| Revenue Next Year | $15.68 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.84 | $2.90 |
| 52 Week High | $2.38 | $10.99 |
Technical Indicators
Market Signals| Indicator | CGC | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 44.05 | 33.70 |
| Support Level | $0.99 | $4.47 |
| Resistance Level | $1.23 | $6.26 |
| Average True Range (ATR) | 0.05 | 0.34 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 40.22 | 4.51 |
Price Performance
Historical ComparisonAbout CGC Canopy Growth Corporation
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.